Tumor vessel co-option probed by single-cell analysis

Teuwen, LA; De Rooij, LPMH; Cuypers, A; Rohlenova, K; Dumas, SJ; Garcia-Caballero, M; Meta, E; Amersfoort, J; Taverna, F; Becker, LM; Veiga, N; Cantelmo, AR; Geldhof, V; Conchinha, NV; Kalucka, J; Treps, L; Conradi, LC; Khan, S; Karakach, TK; Soenen, S; Vinckier, S; Schoonjans, L; Eelen, G; Van Laere, S; Dewerchin, M; Dirix, L; Mazzone, M; Luo, YL; Vermeulen, P; Carmeliet, P

Carmeliet, P (corresponding author), Katholieke Univ Leuven, Leuven Canc Inst, Dept Oncol, VIB,Ctr Canc Biol CCB,Lab Angiogenesis & Vasc Met, B-3000 Leuven, Belgium.; Carmeliet, P (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.; Luo, YL (corresponding author), Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.; Luo, YL (corresponding author), BGI Qingdao, Lars Bolund Inst Regenerat Med, Qingdao 266555, Peop

CELL REPORTS, 2021; 35 (11):

Abstract

Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted end......

Full Text Link